Chemoablation expands treatment options for recurrent LG-IR-NMIBC

Chemoablation using the FDA-approved mitomycin intravesical solution (Zusduri) is expanding treatment options for recurrent low-grade, intermediate-risk non–muscle-invasive bladder cancer, offering a non-surgical alternative with efficacy across various patient groups. The ENVISION study supports its use especially for patients with frequent recurrences or complications from traditional surgery.

This Wire brief sits within Fusion42's coverage of Health.